---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-111974"
form_type: "8-K"
ticker: "ITRMF"
cik: "0001659323"
company_name: "Iterum Therapeutics plc"
filed_at: "2025-08-28T23:59:59+00:00"
generated_at: "2026-05-17T09:28:35.752533+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Iterum Therapeutics receives Nasdaq delisting notice for bid price below $1.00

## Summary
- Nasdaq notice for non-compliance with minimum bid price rule; shares traded below $1.00 for 30 consecutive business days.
- 180-day cure period expires February 23, 2026; must close at $1.00 for 10 consecutive business days to regain compliance.
- May qualify for an additional 180-day period if it meets other listing standards and intends to cure via reverse split.
- Failure to cure could lead to delisting; company will monitor options but no assurance of regaining compliance.

## SEC filing metadata
- accession: 0000950170-25-111974
- form_type: 8-K
- ticker: ITRMF
- cik: 0001659323
- company_name: Iterum Therapeutics plc
- filed_at: 2025-08-28T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659323/000095017025111974/0000950170-25-111974-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659323/000095017025111974/itrm-20250825.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-111974
- JSON: https://secwatch.observer/filing/0000950170-25-111974.json
- Plain text: https://secwatch.observer/filing/0000950170-25-111974.txt

## Key facts
- Listing & Compliance Notices
  Iterum Therapeutics plc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: August 25, 2025, Iterum Therapeutics plc (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (“Nasdaq”) indicating that, based on the closing bid price for the last 30 consecutive business days, the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company maintain a minimum bid price of $1.00 per share (the “Bid Price Rule”) for continued listing on The Nasdaq Capital Market. The Notice does not result in the immediate delisting of the Company’s ordinary shares from The Nasdaq Capital Ma
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659323/000095017025111974/0000950170-25-111974-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.